FDA can and should do more to monitor the cannabidiol product space, specifically by requiring all companies that make CBD consumer products register with the agency, a former FDA official told Inside Health Policy . Though FDA has authority to do that right now, the former official believes the agency may have delayed taking certain action because of a lack of permanent leadership and a desire to walk a fine political line. Representatives from an array of sectors, including hemp...